Sex Differences in Comorbidity Combinations in the Swedish Population

Biomolecules. 2022 Jul 6;12(7):949. doi: 10.3390/biom12070949.

Abstract

High comorbidity rates, especially mental-physical comorbidity, constitute an increasing health care burden, with women and men being differentially affected. To gain an overview of comorbidity rates stratified by sex across a range of different conditions, this study examines comorbidity patterns within and between cardiovascular, pulmonary, skin, endocrine, digestive, urogenital, musculoskeletal, neurological diseases, and psychiatric conditions. Self-report data from the LifeGene cohort of 31,825 participants from the general Swedish population (62.5% female, 18-84 years) were analyzed. Pairwise comorbidity rates of 54 self-reported conditions in women and men and adjusted odds ratios (ORs) for their comparison were calculated. Overall, the rate of pairwise disease combinations with significant comorbidity was higher in women than men (14.36% vs. 9.40%). Among psychiatric conditions, this rate was considerably high, with 41.76% in women and 39.01% in men. The highest percentages of elevated mental-physical comorbidity in women were found for musculoskeletal diseases (21.43%), digestive diseases (20.71%), and skin diseases (13.39%); in men, for musculoskeletal diseases (14.29%), neurological diseases (11.22%), and digestive diseases (10%). Implications include the need for integrating mental and physical health care services and a shift from a disease-centered to an individualized, patient-centered focus in clinical care.

Keywords: comorbidity; digestive; diseases; health; musculoskeletal; neurological; psychiatric; sex; skin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Comorbidity
  • Female
  • Humans
  • Male
  • Mental Disorders* / epidemiology
  • Musculoskeletal Diseases* / epidemiology
  • Sex Characteristics
  • Sweden / epidemiology

Grants and funding

This research was funded by the European Union′s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 764604, the European Union’s Horizon 2020 Research and Innovation Programme, grant agreement No. 848261 as well as by the GENDER-Net Co-Plus Fund (GNP-182).